Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly

Herbert A. Schmid, Thierry Brue, Annamaria Colao, Mônica R. Gadelha, Ilan Shimon, Karen Kapur, Alberto M. Pedroncelli, Maria Fleseriu

Research output: Contribution to journalArticle

31 Scopus citations


The purpose of this study was to gain more insight into the mechanism of action of pasireotide in patients who completed the PAOLA study. PAOLA was a 24-week, Phase III, randomized, three-arm study of pasireotide LAR 40 and 60 mg versus octreotide LAR 30 mg or lanreotide Autogel 120 mg in patients with inadequately controlled acromegaly. The current work was a planned exploratory objective of the PAOLA study that evaluated changes in levels of growth hormone (GH), insulin-like growth factor 1 (IGF-1), IGF-binding proteins (IGFBP-2, IGFBP-3), glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) in each treatment arm. Responders to pasireotide LAR (mean GH levels

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
StateAccepted/In press - Feb 23 2016



  • Acromegaly
  • Glucose
  • HbA
  • Hyperglycaemia
  • Pasireotide

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this